Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease — Stella

Home/Systemic Lupus Erythematosus (SLE)/

View on ClinicalTrials.gov

Recruiting

Back to Systemic Lupus Erythematosus (SLE) trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Shanghai ChangZheng hospital, Shanghai

Key details

Sponsor

Shanghai Changzheng Hospital

Enrollment target

~6 participants

Started

April 2024

Primary completion

April 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 65 Years

Last updated April 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.